Arzoxifene
- Generic Name
- Arzoxifene
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C28H29NO4S
- CAS Number
- 182133-25-1
- Unique Ingredient Identifier
- E569WG6E60
- Indication
Investigated for use/treatment in breast cancer, osteoporosis, and endometrial cancer.
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Arzoxifene to Treat Korean Women With Osteoporosis
- First Posted Date
- 2008-10-07
- Last Posted Date
- 2015-04-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 91
- Registration Number
- NCT00767299
- Locations
- ๐ฐ๐ท
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of
Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis
- First Posted Date
- 2006-10-03
- Last Posted Date
- 2010-01-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 320
- Registration Number
- NCT00383422
- Locations
- ๐จ๐ณ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tao-Yuan, Taiwan
A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-05-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 70
- Registration Number
- NCT00190697
- Locations
- ๐บ๐ธ
For information regarding investigative sites for this clinical trial, call 1-877- CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or contact your personal physician, Houston, Texas, United States
Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer
- First Posted Date
- 2004-07-20
- Last Posted Date
- 2010-06-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 9369
- Registration Number
- NCT00088010
- Locations
- ๐บ๐ธ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Elk Grove, Illinois, United States
Effects of Arzoxifene on Bone Mass and the Uterus
- Conditions
- First Posted Date
- 2004-06-22
- Last Posted Date
- 2007-03-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 300
- Registration Number
- NCT00085956
- Locations
- ๐บ๐ธ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Diego, California, United States
LY353381 in Preventing Breast Cancer in Women With Hyperplasia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 199
- Registration Number
- NCT00005879
- Locations
- ๐บ๐ธ
U.S. Oncology Research, Inc., Dallas, Texas, United States
๐บ๐ธUniversity of Kansas Medical Center, Kansas City, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.